Pharvaris CMO sells 18,733 shares in planned trade

Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan. Peng exercised options to acquire 18,733 shares of common stock at $2.59 per share and sold the same number of shares in open-market transactions at weighted average prices around $30 on April 29–30, 2026.

Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock and 219,474 stock options from the referenced grant, which remains outstanding until February 3, 2030.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,733 shares ($517K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Lu Peng

Role Chief Medical Officer

Sold 18,733 shs ($566K)

Approx. gross sale proceeds $566K

Approx. exercise cost $49K

Approx. pre-tax spread $517K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$2.59	$39K
Sale	Common Stock	15,000	$30.2418	$454K
Exercise	Stock Option (Right to Buy)	3,733	$0.00	$0.00
Exercise	Common Stock	3,733	$2.59	$10K
Sale	Common Stock	3,733	$30.0649	$112K

Holdings After Transaction: Stock Option (Right to Buy) — 219,474 contracts (Direct); Common Stock — 66,083 shares (Direct)

Footnotes (5)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.75 to $30.2418. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
4. F4. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. F5. The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction.

Key Figures

Shares sold: 18,733 shares Exercise price: $2.59 per share Weighted average sale price 4/29: $30.0649 per share +4 more

7 metrics

Shares sold 18,733 shares Total common shares sold in open-market trades on April 29–30, 2026

Exercise price $2.59 per share Strike price for options exercised for 18,733 common shares

Weighted average sale price 4/29 $30.0649 per share Common stock sales on April 29, 2026; prices ranged $30.00–$30.20

Weighted average sale price 4/30 $30.2418 per share Common stock sales on April 30, 2026; prices ranged $30.75–$30.2418

Shares owned after trades 66,083 shares Common shares directly owned by Lu Peng following transactions

Options remaining 219,474 options Derivative securities beneficially owned after transactions from referenced grant

Option expiration February 3, 2030 Expiration date of the stock option grant exercised in part

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), restricted stock units, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

restricted stock units financial

"shares of common stock acquired upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative securities beneficially owned financial

"The number of derivative securities beneficially owned following the reported transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Pharvaris (PHVS) CMO Lu Peng report?

Lu Peng reported exercising options for 18,733 Pharvaris shares at $2.59 and selling 18,733 common shares in open-market trades around $30. The transactions occurred on April 29–30, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares did Lu Peng sell in this Form 4 filing?

Lu Peng sold a total of 18,733 Pharvaris common shares in open-market transactions. These included 3,733 shares on April 29, 2026, at a weighted average of $30.0649 and 15,000 shares on April 30, 2026, at a weighted average of $30.2418.

At what prices did Pharvaris (PHVS) CMO Lu Peng sell company shares?

Lu Peng’s reported sales used weighted average prices. On April 29, 2026, shares sold around $30.0649 within a $30.00–$30.20 range. On April 30, 2026, shares sold around $30.2418 within a $30.75–$30.2418 range, under a Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares and options does Lu Peng own after the Form 4 trades?

After the reported transactions, Lu Peng directly owns 66,083 Pharvaris common shares. In addition, the filing shows 219,474 stock options from the referenced grant beneficially owned following the transactions, with an expiration date of February 3, 2030.

Were Lu Peng’s Pharvaris (PHVS) share sales pre-planned under a Rule 10b5-1 plan?

Yes. Footnotes state these were scheduled exercises and sales executed under a Rule 10b5-1 trading plan. Such plans pre-arrange trade timing and amounts, indicating the transactions followed a predetermined schedule rather than being discretionary market-timing decisions.

What is the strike price and expiration of Lu Peng’s exercised Pharvaris (PHVS) options?

The options exercised to acquire 18,733 Pharvaris shares had a strike price of $2.59 per share and an expiration date of February 3, 2030. Footnotes note 25% vested on February 3, 2021, with remaining shares vesting in equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 07:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Peng

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		M(1)		3,733	A	$2.59	69,816	D
Common Stock	04/29/2026		S(1)		3,733	D	$30.0649(2)	62,350	D
Common Stock	04/30/2026		M(1)		15,000	A	$2.59	81,083	D
Common Stock	04/30/2026		S(1)		15,000	D	$30.2418(3)	66,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	04/29/2026		M			3,733	(4)	02/03/2030	Common Stock	3,733	$0	234,474(5)	D
Stock Option (Right to Buy)	$2.59	04/30/2026		M			15,000	(4)	02/03/2030	Common Stock	15,000	$0	219,474(5)	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.75 to $30.2418. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction.

	/s/ Marnus Nel, Attorney-in-Fact for Peng Lu	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)